Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May;10(5):833-9.
doi: 10.1111/j.1538-7836.2012.04669.x.

A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis

S W Rathbun  1 , C E Aston, T L Whitsett
Affiliations
Randomized Controlled Trial

A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis

S W Rathbun et al. J Thromb Haemost. 2012 May.

Abstract

Background: Superficial thrombophlebitis can produce pain and result in a deep vein thrombosis (DVT) if not treated. Conservative therapies including prescription of non-steroidal anti-inflammatory drugs (NSAID) and heat have been standard care. Recently, studies have been published reporting efficacy and safety of low-molecular-weight heparin for the treatment of superficial thrombophlebitis. However, there are few comparative trials to conservative therapy. We studied the effectiveness and safety of treatment with dalteparin compared with ibuprofen in patients with confirmed superficial thrombophlebitis.

Methods: Consecutive patients were randomized to receive daily dalteparin vs. ibuprofen three times daily for up to 14 days. The primary outcome measure was the incidence of extension of thrombus or new symptomatic venous thromboembolism during the 14-day and 3-month follow-up period. The secondary outcome was a reduction in pain. The outcome measure of safety was the incidence of major and minor bleeding.

Results: Of 302 consecutive patients screened, 72 were enrolled. Four patients receiving ibuprofen compared with no patients receiving dalteparin had thrombus extension at 14 days (P = 0.05), however, there was no difference in thrombus extension at 3 months. Both treatments significantly reduced pain. There were no episodes of major or minor bleeding during the treatment period.

Conclusions: Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding. However, questions concerning the optimal treatment duration should be explored in future trials.

Trial registration: ClinicalTrials.gov NCT00264381.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment algorithm
Figure 2
Figure 2
Change in pain scores during initial 14 day treatment
See this image and copyright information in PMC

References

    1. Sullivan V, Denk P, Sonnad S, Eagleton M, Wakefield T. Ligation versus Anticoagulation: Treatment of Above-Knee Superficial Thrombophlebitis not Involving the Deep Venous System. J Am Coll Surg. 2001;193:556–62. - PubMed
    1. Bounameaux H, Reber-Wasem M. Superficial Thrombophlebitis and Deep Venous Thrombosis. Arch Intern Med. 1997;157:1822–4. - PubMed
    1. Blumenberg R, Barton E, Gelfand M, Skudder P, Brennan J. Occult deep venous thrombosis complicating superficial thrombophlebitis. J Vasc Surg. 1998;27:338–43. - PubMed
    1. Belcaro G, Nicolaides A, Errichi B, et al. Superficial Thrombophlebitis of the Legs: A Randomized, Controlled, Follow-up Study. Angiology. 1999;50:523–9. - PubMed
    1. Messmore H, Bishop M, Wehrmacher W. Acute venous thrombosis: Therapeutic choices for superficial and deep veins. Postgraduate Medicine. 1991;89:73–7. - PubMed

Publication types

MeSH terms

Associated data